title: [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy].
abstract: We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy. A 63-year-old female was in hospital for treatment of hepatic tumor in left lobe with portal venous tumor thrombus. She was treated by IFN-alpha/5-FU chemotherapy, and the tumor was significantly reduced. For 28 months, the tumor was successfully treated by IFN-alpha/5-FU chemotherapy. But, thereafter the abdominal computed tomography showed the tumor re-growth and invasion to the diaphragm. Then the patient underwent the tumor resection. The histological findings were consistent with combined hepatocellular and cholangiocarcinoma. Immunohistological examination revealed a heterogeneous expression of IFN-alpha receptor 2. This case suggested that the growth of cancer cells without sensitivity to IFN-alpha/5-FU chemotherapy and the blood supply via the diaphragm led the relapse of IFN-alpha/5-FU chemotherapy.
authors.affiliation: Dept. of Surgery, Graduate School of Medicine, Osaka University.
authors.forename: Takehiro
authors.initials: T
authors.lastname: Noda
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
authors.forename: Shigeru
authors.initials: S
authors.lastname: Marubashi
authors.forename: Shogo
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takeda
authors.forename: Masahiro
authors.initials: M
authors.lastname: Murakami
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Tomimaru
authors.forename: Keizo
authors.initials: K
authors.lastname: Dono
authors.forename: Koji
authors.initials: K
authors.lastname: Umeshita
authors.forename: Mika
authors.initials: M
authors.lastname: Nakayama
authors.forename: Toshihide
authors.initials: T
authors.lastname: Shima
authors.forename: Kenichi
authors.initials: K
authors.lastname: Wakasa
authors.forename: Morito
authors.initials: M
authors.lastname: Monden
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D018281:Cholangiocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003964:Diaphragm / Q000187:drug effects / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007261:Infusions, Intra-Arterial; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D019042:Muscle Neoplasms / Q000556:secondary*; D009361:Neoplasm Invasiveness / Q000473:pathology; D014057:Tomography, X-Ray Computed; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D016898:Interferon-alpha; D000509:alpha-Fetoproteins; D005472:Fluorouracil